Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of MB-CART2019.1 in relapsed/refractory DLBCL
jRCT2033250384Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Jan 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zamtocabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Miltenyi Biomedicine GmbH. Primary endpoint: Objective response rate at 1 month. Started Jan 2026; status: recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2033250384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250384.